Cargando…

Immune checkpoint inhibitors and response analysis: a tough challenge. A case report

BACKGROUND: Treatment of metastatic NSCLC patients with immune-checkpoint medicine is intriguing for the potential efficacy; however it may be difficult to evaluate the clinical response due to the lack of reliable immune-monitoring markers up to now and the possibility of radiological pseudo-progre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bearz, Alessandra, Perin, Tiziana, Cancian, Luca, Berto, Eleonora, Sartor, Ivana, Tirelli, Umberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950698/ https://www.ncbi.nlm.nih.gov/pubmed/27431235 http://dx.doi.org/10.1186/s13104-016-2153-9

Ejemplares similares

Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
por: Marmorino, Federica, et al.
Publicado: (2020)

Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report
por: Bearz, Alessandra, et al.
Publicado: (2014)

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
por: Bearz, Alessandra, et al.
Publicado: (2012)

Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors
por: Muraro, Elena, et al.
Publicado: (2023)

Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications
por: Del Conte, Alessandro, et al.
Publicado: (2022)

Immune checkpoint inhibitors in lymphoma: challenges and opportunities
por: Hatic, Haris, et al.
Publicado: (2021)

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience
por: De Carlo, Elisa, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge
por: Catalano, Martina, et al.
Publicado: (2022)

Progress and Challenges of Immune Checkpoint Inhibitor-Induced Hypophysitis
por: Chen, Piaohong, et al.
Publicado: (2023)

Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
por: Bianco, Andrea, et al.
Publicado: (2019)

Indicators of responsiveness to immune checkpoint inhibitors
por: Shields, Bradley D., et al.
Publicado: (2017)

Target Therapies in Lung Cancer
por: Bearz, A., et al.
Publicado: (2011)

Tough challenges for testing Ebola therapeutics
Publicado: (2015)

Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma
por: Sanders, Stephanie, et al.
Publicado: (2020)

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
por: Taghizadeh, H., et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
por: Makaremi, Shima, et al.
Publicado: (2021)

Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
por: Dobosz, Paula, et al.
Publicado: (2022)

Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future
por: Zhang, Zeng, et al.
Publicado: (2022)

Tough antigens trigger immunity
por: Van Epps, Heather L.
Publicado: (2006)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Biomarkers of therapeutic response with immune checkpoint inhibitors
por: Bindal, Poorva, et al.
Publicado: (2021)

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era
por: De Carlo, Elisa, et al.
Publicado: (2022)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges
por: Regzedmaa, Orgilmaa, et al.
Publicado: (2019)

Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects
por: Chen, Xunrui, et al.
Publicado: (2022)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
por: Xie, Qingqing, et al.
Publicado: (2022)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
por: Joseph, Gwenyth J., et al.
Publicado: (2023)

Immune checkpoint inhibitors in penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2021)

Tough Mining: The challenges of searching the scientific literature
por: Dickman, Steven
Publicado: (2003)

Pseudoachalasia: Still a Tough Clinical Challenge
por: Jia, Yi, et al.
Publicado: (2015)

The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
por: Bearz, Alessandra, et al.
Publicado: (2022)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Personeni, Nicola, et al.
Publicado: (2021)

Comment on ‘Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection’
por: Bearz, A, et al.
Publicado: (2012)

Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
por: Li, Meng, et al.
Publicado: (2022)

Response: Getting Tough with Smoking
por: Covey, Lirio S., et al.
Publicado: (2003)

Hallmarks of Resistance to Immune-Checkpoint Inhibitors
por: Karasarides, Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v65hr00a14ukkh6i8kc5drflo7